Policy & Regulation
FDA workshop uses ALS brain implants as its case study for small device trials
At a September FDA workshop on rare disease statistics, the FDA's background paper on device studies used brain-computer interfaces for ALS as its case example for testing devices in small populations. An FDA official said more uncertainty before approval may be acceptable when it is paired with post-market data collection, Synchron's Adam Fry said he does not think implant trials can be blinded effectively or ethically, and Paradromics said it is using its Connect-One study to design the measures for its pivotal trial.